These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20832143)

  • 21. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei.
    Wiersinga WJ; van der Poll T; White NJ; Day NP; Peacock SJ
    Nat Rev Microbiol; 2006 Apr; 4(4):272-82. PubMed ID: 16541135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycotic aneurysm in Northeast Thailand: the importance of Burkholderia pseudomallei as a causative pathogen.
    Anunnatsiri S; Chetchotisakd P; Kularbkaew C
    Clin Infect Dis; 2008 Dec; 47(11):1436-9. PubMed ID: 18937581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of the disinfectant activity of the compound VIRKON].
    Ricci A; Carnuccio V; Suzzi R; Pascali A; Gasponi A; Bolognesi V; Bolognesi E
    Ann Ig; 1995; 7(1):27-33. PubMed ID: 8663961
    [No Abstract]   [Full Text] [Related]  

  • 24. Characterization of Burkholderia pseudomallei isolated in Thailand and Malaysia.
    Radua S; Ling OW; Srimontree S; Lulitanond A; Hin WF; Yuherman ; Lihan S; Rusul G; Mutalib AR
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):141-5. PubMed ID: 11109011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of biapenem against Burkholderia pseudomallei.
    Thamlikitkul V; Trakulsomboon S
    Int J Antimicrob Agents; 2010 May; 35(5):514. PubMed ID: 20188524
    [No Abstract]   [Full Text] [Related]  

  • 26. Antimycobacterial activity of 'Virkon'.
    Broadley SJ; Furr JR; Jenkins PA; Russell AD
    J Hosp Infect; 1993 Mar; 23(3):189-97. PubMed ID: 8099093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An in situ high-throughput screen identifies inhibitors of intracellular
    Bulterys PL; Toesca IJ; Norris MH; Maloy JP; Fitz-Gibbon ST; France B; Toffig B; Morselli M; Somprasong N; Pellegrini M; Schweizer HP; Tuanyok A; Damoiseaux R; French CT; Miller JF
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18597-18606. PubMed ID: 31439817
    [No Abstract]   [Full Text] [Related]  

  • 28. Case Report: Chorioamnionitis and Premature Delivery due to
    Porter MC; Pennell CE; Woods P; Dyer J; Merritt AJ; Currie BJ
    Am J Trop Med Hyg; 2018 Mar; 98(3):797-799. PubMed ID: 29363450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycotic iliac aneurysm associated with Burkholderia pseudomallei.
    Amezyane T; Lecoules S; Algayres JP
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e381-2. PubMed ID: 19897393
    [No Abstract]   [Full Text] [Related]  

  • 30. [Evaluation of the antiviral activity of the disinfectant VIRKON].
    Bonfanti C; Pollara P; De Rango C; Turano A
    Ann Ig; 1995; 7(1):55-62. PubMed ID: 8663967
    [No Abstract]   [Full Text] [Related]  

  • 31. The action of VIRKON No Foam on the hepatitis B virus.
    Scioli D; Pizzella T; Vollaro L; Nardiello S; De Feo L
    Eur J Epidemiol; 1997 Dec; 13(8):879-83. PubMed ID: 9476816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of ceftazidime resistance in Burkhoderia pseudomallei in a patient experiencing melioidosis with mediastinal lymphadenitis.
    Kung CT; Lee CH; Li CJ; Lu HI; Ko SF; Liu JW
    Ann Acad Med Singap; 2010 Dec; 39(12):945-3. PubMed ID: 21274496
    [No Abstract]   [Full Text] [Related]  

  • 33. Cross-reactivity of latex agglutination assay complicates the identification of Burkholderia pseudomallei from soil.
    Songsri J; Kinoshita Y; Kwanhian W; Wisessombat S; Tangpong J; Rahman-Khan MS; Tuanyok A
    FEMS Microbiol Lett; 2018 Nov; 365(22):. PubMed ID: 30346523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of mycobactericidal activity of the disinfectant VIRKON by polymerase chain reaction (PCR)].
    Vollaro L; Scioli C
    Ann Ig; 1995; 7(1):49-53. PubMed ID: 8663965
    [No Abstract]   [Full Text] [Related]  

  • 35. Two-Center Evaluation of Disinfectant Efficacy against Ebola Virus in Clinical and Laboratory Matrices.
    Smither SJ; Eastaugh L; Filone CM; Freeburger D; Herzog A; Lever MS; Miller DM; Mitzel D; Noah JW; Reddick-Elick MS; Reese A; Schuit M; Wlazlowski CB; Hevey M; Wahl-Jensen V
    Emerg Infect Dis; 2018 Jan; 24(1):135-9. PubMed ID: 29261093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct Pathogenic Patterns of
    Chen YL; Hsu DW; Hsueh PT; Chen JA; Shih PJ; Lee S; Lin HH; Chen YS
    Am J Trop Med Hyg; 2019 Oct; 101(4):736-745. PubMed ID: 31392941
    [No Abstract]   [Full Text] [Related]  

  • 37. Biochemical characteristics of clinical and environmental isolates of Burkholderia pseudomallei.
    Wuthiekanun V; Smith MD; Dance DA; Walsh AL; Pitt TL; White NJ
    J Med Microbiol; 1996 Dec; 45(6):408-12. PubMed ID: 8958243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia pseudomallei cause disease?
    Lazar Adler NR; Govan B; Cullinane M; Harper M; Adler B; Boyce JD
    FEMS Microbiol Rev; 2009 Nov; 33(6):1079-99. PubMed ID: 19732156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology of Burkholderia pseudomallei in Thailand.
    Vuddhakul V; Tharavichitkul P; Na-Ngam N; Jitsurong S; Kunthawa B; Noimay P; Noimay P; Binla A; Thamlikitkul V
    Am J Trop Med Hyg; 1999 Mar; 60(3):458-61. PubMed ID: 10466977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imported melioidosis in Danish travellers: a diagnostic challenge.
    Badran S; Pedersen TI; Roed C; Lunding S; Birk N; Vestergaard H; Røder B; Lillelund HK; Kurtzhals JA; Kemp M; Christensen JJ
    Scand J Infect Dis; 2010 Jul; 42(6-7):445-9. PubMed ID: 20297927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.